








## DRUG METABOLISM AND PHARMACOKINETICS (DMPK)

## Trends in DMPK

Key aspects focused on during drug discovery included:







80


70

60

66%

Radioactivity

studies



19%

20

30

%

50

60

70

80

10

Top 3 challenges of analyzing DMPK:

**52%** 50

Radioactivity



**26%** 

Historial

data

**DECREASED** 

25%

Company

reputation

100

38%

Price

## 100

20%

80

The future of DMPK

The number of DMPK studies

conducted over the last 5 years has:

80%

Data

quality

STAYED THE SAME 20% 60

80 **STAY THE 16%** SAME 60

7%

N/A

In the next 5 years, the percentage

of DMPK studies will:


21%

1%

Other

**DECREASE** 





39% 31% Biotechnology Director/CEO/VP 16% 24% Large pharma Manager/Group Leader 18% 33% Small/Mid-size pharma Technician 18% 1% Generic pharma Other 9% 3% Equipment vendor 2% Other 6%

This infographic has been created as part of a Bioanalysis Zone feature in association with QPS and SCIEX.





